Alexion Pharmaceuticals Inc. (ALXN)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

121 SEAPORT BOULEVARD BOSTON, MA 02210

Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. As a leader in rare diseases for more than 25 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D) as well as the first and only approved Factor Xa inhibitor reversal agent. In addition, the company is developing several mid-to-late-stage therapies, including a copper-binding agent for Wilson disease, an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases and an oral Factor D inhibitor as well as several early-stage therapies, including one for light chain (AL) amyloidosis, a second oral Factor D inhibitor and a third complement inhibitor. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology, ophthalmology and acute care. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.

Data as of 2021-07-19 08:13:22 -0400
Market Cap39.79 Billion Shares Outstanding221.019 Million Avg 30-day Volume3.653 Million
P/E Ratio58.36036 Dividend Yield EPS3.07
Price/Sales6.35 Debt to Equity1.5 EBITDA3.18 Billion
Price to Book Value3.2 Forward PE0.83 Enterprise Value38.853 Billion
Total Cash3.469 Billion Current Debt1.426 Billion Gross Profit5.694 Billion
BETA0.73171 52-week High/Low187.45 / 99.91 Next Earnings Date2021-07-29 Price to Cash FLow (P/CF) 74.4628
Data provided by IEX Cloud
View SEC Filings from ALXN instead.
Q1 2021 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 62 40 55.0% 39 (2.29%) 24 (1.39%) 62.5%
Funds Holding: 725 797 -9.03% 187 (10.97%) 206 (11.96%) -9.22%
13F shares: 183.291 Million 192.9 Million -4.98% 63.984 Million 64.547 Million -0.87%
% Ownership 83.3718 88.1946 -5.47% 29.1039 29.5114 -1.38%
New Positions: 79 192 -58.85% 28 71 -60.56%
Increased Positions 233 236 -1.27% 86 62 38.71%
Closed Positions 144 77 87.01% 45 23 95.65%
Reduced Positions 307 279 10.04% 60 59 1.69%
Total Calls 1.358 Million 3.559 Million -61.83% 798.9 Thousand 1.406 Million -43.16%
Total Puts 1.747 Million 2.946 Million -40.69% 1.054 Million 783 Thousand 34.55%
PUT/CALL Ratio 1.29 0.83 55.42% 1.32 0.56 135.71%
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding ALXN (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ALXN BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

RUMMELT ANDREAS

  • Director
0 2021-07-21 2

MOLLEN JOHN T

  • Director
0 2021-07-21 2

BRENNAN DAVID R

  • Director
0 2021-07-21 2

COUGHLIN CHRISTOPHER J

  • Director
0 2021-07-21 2

HANTSON LUDWIG CEO

  • Officer
  • Director
9,098 2021-07-21 5

ORLOFF JOHN J EVP, RESEARCH & DEVELOPMENT

  • Officer
0 2021-07-21 5

GOFF BRIAN EVP & CHIEF COMMERCIAL OFFICER

  • Officer
0 2021-07-21 5

FRANCHINI INDRANI LALL EVP, CHIEF COMPLIANCE OFFICER

  • Officer
0 2021-07-21 5

FRIEDMAN PAUL A

  • Director
0 2021-07-21 2

NADER FRANCOIS

  • Director
0 2021-07-21 2

DUNSIRE DEBORAH

  • Director
0 2021-07-21 2

REINSDORF JUDITH A

  • Director
0 2021-07-21 2

CHINIARA ELLEN EVP & CHIEF LEGAL OFFICER

  • Officer
0 2021-07-21 4

SARIN ARADHANA EVP, CFO

  • Officer
0 2021-07-21 5

BAZARKO DANIEL SVP, CONTROLLER, CAO

  • Officer
0 2021-07-21 5

CARINO TANISHA EVP & CCAO

  • Officer
0 2021-07-21 4

LAW ANNE-MARIE EVP, CHIEF EXPERIENCE OFFICER

  • Officer
41,423 2020-06-08 0

BAKER BROS. ADVISORS LP

667, L.P.

BAKER BROS. ADVISORS (GP) LLC

BAKER BROTHERS LIFE SCIENCES LP

BAKER FELIX

BAKER JULIAN

  • Director
9,071,539 2020-05-14 0

CLANCY PAUL J EVP, CHIEF FINANCIAL OFFICER

  • Officer
90,447 2019-07-11 0

O'NEILL JULIE EVP. GLOBAL OPERATIONS

  • Officer
51,727 2018-02-28 0

WAGNER HEIDI L SVP, GLOBAL GOVERNMENT AFFAIRS

  • Officer
49,140 2018-02-27 0

MORIARTY JOHN B EVP & GENERAL COUNSEL

  • Officer
74,537 2018-02-06 0

VENEMAN ANN M

  • Director
5,480 2017-09-05 0

PARVEN ALVIN S

  • Director
7,568 2017-06-15 0

NORBY R DOUGLAS

  • Director
4,906 2017-05-10 0

BURNS M MICHELE

  • Director
4,353 2017-05-10 0

BELL LEONARD

  • Director
390,670 2017-02-28 0

THIEL CARSTEN EVP, CHIEF COMMERCIAL OFFICER

  • Officer
33,860 2017-02-28 0

CARMICHAEL CLARE EVP, CHIEF HR OFFICER

  • Officer
39,161 2017-02-27 0

MACKAY MARTIN EVP & GLOBAL HEAD OF R&D

  • Officer
50,688 2017-02-27 0

MILLER EDWARD SVP, CHIEF COMPLIANCE OFFICER

  • Officer
19,284 2017-02-27 0

ANDERSON DAVID J EVP, CHIEF FINANCIAL OFFICER

  • Officer
0 2016-12-12 0

SINHA VIKAS EVP & CFO

  • Officer
178,463 2016-08-08 0

HALLAL DAVID CEO

  • Officer
  • Director
189,266 2016-08-08 0

ISLAM SAQIB EVP, CHIEF STRAT & PORT. OFF.

  • Officer
43,799 2016-02-29 0

MONNET DOMINIQUE SVP, CHIEF MARKETING OFFICER

  • Officer
8,787 2015-05-20 0

KELLER WILLIAM R

  • Director
7,276 2014-12-04 0

SQUINTO STEPHEN P EVP, CHIEF GLOBAL OPS. OFFICER

  • Officer
106,508 2014-10-27 0

LINK MAX

  • Director
0 2014-05-05 0

MADRI JOSEPH A

  • Director
179,217 2014-03-11 0

MATHIS LARRY

  • Director
30,351 2014-02-28 0

WRIGHT FRANK J SVP, PRESIDENT ALXN PHARM INTL

  • Officer
19,670 2014-02-06 0

COISSAC PATRICE SVP & PRES. ALXN PHARMA INT'L

  • Officer
1,118 2012-10-31 0

DUBIN THOMAS I H SVP & CHIEF LEGAL OFFICER

  • Officer
65,705 2012-08-23 0

WAEGER RUEDI E

  • Director
24,054 2010-05-03 0

KEISER DAVID W

  • Director
149,546 2009-06-01 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

BAZARKO DANIEL - Officer SVP, CONTROLLER, CAO

2021-07-23 16:39:10 -0400 2021-07-21 D 5,111 $176.80 d 0 direct

CHINIARA ELLEN - Officer EVP & CHIEF LEGAL OFFICER

2021-07-23 16:40:38 -0400 2021-07-21 D 116,850 d 0 direct

FRANCHINI INDRANI LALL - Officer EVP, CHIEF COMPLIANCE OFFICER

2021-07-23 16:37:55 -0400 2021-07-21 D 116,075 d 0 direct

RUMMELT ANDREAS - Director

2021-07-23 16:34:17 -0400 2021-07-21 D 2,343 $155.01 d 0 direct

COUGHLIN CHRISTOPHER J - Director

2021-07-23 16:54:11 -0400 2021-07-21 D 2,706 $167.97 d 0 direct

RUMMELT ANDREAS - Director

2021-07-23 16:34:17 -0400 2021-07-21 D 2,294 $138.86 d 0 direct

GOFF BRIAN - Officer EVP & CHIEF COMMERCIAL OFFICER

2021-07-23 16:42:07 -0400 2021-07-21 D 21,750 $100.14 d 0 direct

FRIEDMAN PAUL A - Director

2021-07-23 16:51:08 -0400 2021-07-21 D 12,840 d 0 direct

MOLLEN JOHN T - Director

2021-07-23 16:45:40 -0400 2021-07-21 D 2,785 $159.70 d 0 direct

DUNSIRE DEBORAH - Director

2021-07-23 16:48:29 -0400 2021-07-21 D 14,629 d 0 direct

BRENNAN DAVID R - Director

2021-07-23 16:44:13 -0400 2021-07-21 D 2,706 $167.97 d 0 direct

BAZARKO DANIEL - Officer SVP, CONTROLLER, CAO

2021-07-23 16:39:10 -0400 2021-07-21 D 2,912 $180.28 d 0 direct

BAZARKO DANIEL - Officer SVP, CONTROLLER, CAO

2021-07-23 16:39:10 -0400 2021-07-21 D 5,300 $131.25 d 0 direct

NADER FRANCOIS - Director

2021-07-23 16:36:17 -0400 2021-07-21 D 13,921 d 0 direct

HANTSON LUDWIG - Director - Officer CEO

2021-07-23 16:32:28 -0400 2021-07-21 D 56,762 $118.83 d 0 direct

SARIN ARADHANA - Officer EVP, CFO

2021-07-23 16:52:30 -0400 2021-07-21 D 120,253 d 0 direct

RUMMELT ANDREAS - Director

2021-07-23 16:34:17 -0400 2021-07-21 D 3,237 $85.75 d 0 direct

COUGHLIN CHRISTOPHER J - Director

2021-07-23 16:54:11 -0400 2021-07-21 D 2,294 $138.86 d 0 direct

RUMMELT ANDREAS - Director

2021-07-23 16:34:17 -0400 2021-07-21 D 2,785 $159.70 d 0 direct

GOFF BRIAN - Officer EVP & CHIEF COMMERCIAL OFFICER

2021-07-23 16:42:07 -0400 2021-07-21 D 150,832 d 0 direct

MOLLEN JOHN T - Director

2021-07-23 16:45:40 -0400 2021-07-21 D 2,343 $155.01 d 0 direct

MOLLEN JOHN T - Director

2021-07-23 16:45:40 -0400 2021-07-21 D 15,336 d 0 direct

ORLOFF JOHN J - Officer EVP, RESEARCH & DEVELOPMENT

2021-07-23 16:29:42 -0400 2021-07-21 D 146,511 d 0 direct

BRENNAN DAVID R - Director

2021-07-23 16:44:13 -0400 2021-07-21 D 2,343 $155.01 d 0 direct

BAZARKO DANIEL - Officer SVP, CONTROLLER, CAO

2021-07-23 16:39:10 -0400 2021-07-21 D 3,943 $180.37 d 0 direct

BAZARKO DANIEL - Officer SVP, CONTROLLER, CAO

2021-07-23 16:39:10 -0400 2021-07-21 D 60,207 d 0 direct

FRANCHINI INDRANI LALL - Officer EVP, CHIEF COMPLIANCE OFFICER

2021-07-23 16:37:55 -0400 2021-07-21 D 25,165 $100.14 d 0 direct

HANTSON LUDWIG - Director - Officer CEO

2021-07-23 16:32:28 -0400 2021-07-21 D 580,809 d 9,098 direct

COUGHLIN CHRISTOPHER J - Director

2021-07-23 16:54:11 -0400 2021-07-21 D 2,343 $155.01 d 0 direct

RUMMELT ANDREAS - Director

2021-07-23 16:34:17 -0400 2021-07-21 D 3,425 $96.35 d 0 direct

COUGHLIN CHRISTOPHER J - Director

2021-07-23 16:54:11 -0400 2021-07-21 D 42,347 d 0 direct

RUMMELT ANDREAS - Director

2021-07-23 16:34:17 -0400 2021-07-21 D 28,109 d 0 direct

REINSDORF JUDITH A - Director

2021-07-23 16:49:49 -0400 2021-07-21 D 14,150 d 0 direct

MOLLEN JOHN T - Director

2021-07-23 16:45:40 -0400 2021-07-21 D 2,294 $138.86 d 0 direct

CARINO TANISHA - Officer EVP & CCAO

2021-07-23 16:47:18 -0400 2021-07-21 D 59,226 d 0 direct

BRENNAN DAVID R - Director

2021-07-23 16:44:13 -0400 2021-07-21 D 2,294 $138.86 d 0 direct

BRENNAN DAVID R - Director

2021-07-23 16:44:13 -0400 2021-07-21 D 20,873 d 0 direct

HANTSON LUDWIG - Director - Officer CEO

2021-07-16 16:56:01 -0400 2021-07-14 A 119,847 a 589,907 direct 1.6996 1.6996 2 0.0 1

FRANCHINI INDRANI LALL - Officer EVP, CHIEF COMPLIANCE OFFICER

2021-07-16 16:53:12 -0400 2021-07-14 A 25,813 a 116,075 direct 1.6996 1.6996 2 0.0 1

SARIN ARADHANA - Officer EVP, CFO

2021-07-16 16:54:28 -0400 2021-07-14 A 26,812 a 90,752 direct 1.6996 1.6996 2 0.0 1

CHINIARA ELLEN - Officer EVP & CHIEF LEGAL OFFICER

2021-07-16 16:46:49 -0400 2021-07-14 A 27,657 a 116,850 direct 1.6996 1.6996 2 0.0 1

ORLOFF JOHN J - Officer EVP, RESEARCH & DEVELOPMENT

2021-07-16 16:48:02 -0400 2021-07-14 A 30,643 a 117,010 direct 1.6996 1.6996 2 0.0 1

HANTSON LUDWIG - Director - Officer CEO

2021-07-16 16:56:01 -0400 2021-07-14 A 120,894 a 470,060 direct 1.6996 1.6996 2 0.0 1

FRANCHINI INDRANI LALL - Officer EVP, CHIEF COMPLIANCE OFFICER

2021-07-16 16:53:12 -0400 2021-07-14 A 26,812 a 90,262 direct 1.6996 1.6996 2 0.0 1

BAZARKO DANIEL - Officer SVP, CONTROLLER, CAO

2021-07-16 16:49:36 -0400 2021-07-14 A 10,648 a 60,207 direct 1.6996 1.6996 2 0.0 1

CHINIARA ELLEN - Officer EVP & CHIEF LEGAL OFFICER

2021-07-16 16:46:49 -0400 2021-07-14 A 26,812 a 89,193 direct 1.6996 1.6996 2 0.0 1

GOFF BRIAN - Officer EVP & CHIEF COMMERCIAL OFFICER

2021-07-16 16:43:30 -0400 2021-07-14 A 29,501 a 150,832 direct 1.6996 1.6996 2 0.0 1

CARINO TANISHA - Officer EVP & CCAO

2021-07-16 16:45:11 -0400 2021-07-14 A 25,813 a 59,226 direct 1.6996 1.6996 2 0.0 1

SARIN ARADHANA - Officer EVP, CFO

2021-07-16 16:54:28 -0400 2021-07-14 A 29,501 a 120,253 direct 1.6996 1.6996 2 0.0 1

BAZARKO DANIEL - Officer SVP, CONTROLLER, CAO

2021-07-16 16:49:36 -0400 2021-07-14 A 11,060 a 49,559 direct 1.6996 1.6996 2 0.0 1

ORLOFF JOHN J - Officer EVP, RESEARCH & DEVELOPMENT

2021-07-16 16:48:02 -0400 2021-07-14 A 29,501 a 146,511 direct 1.6996 1.6996 2 0.0 1

GOFF BRIAN - Officer EVP & CHIEF COMMERCIAL OFFICER

2021-07-16 16:43:30 -0400 2021-07-14 A 30,643 a 121,331 direct 1.6996 1.6996 2 0.0 1

FRANCHINI INDRANI LALL - Officer EVP, CHIEF COMPLIANCE OFFICER

2021-06-09 16:50:22 -0400 2021-06-08 F 928 $177.00 d 63,450 direct -0.1868 -1.11 0.0 1 -1.11 6

ORLOFF JOHN J - Officer EVP, RESEARCH & DEVELOPMENT

2021-06-09 16:53:56 -0400 2021-06-08 F 1,957 $177.00 d 86,367 direct -0.1868 -1.11 0.0 1 -1.11 6

GOFF BRIAN - Officer EVP & CHIEF COMMERCIAL OFFICER

2021-06-09 16:52:33 -0400 2021-06-08 F 1,086 $177.00 d 90,688 direct -0.1868 -1.11 0.0 1 -1.11 6

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
ALEXION PHARMACEUTICALS INC ALXN 2021-07-21 22:15:03 UTC -0.1724 0.2524 3900000
ALEXION PHARMACEUTICALS INC ALXN 2021-07-21 21:45:03 UTC -0.1724 0.2524 3900000
ALEXION PHARMACEUTICALS INC ALXN 2021-07-21 21:15:03 UTC -0.1724 0.2524 3900000
ALEXION PHARMACEUTICALS INC ALXN 2021-07-21 20:45:03 UTC -0.17 0.25 3900000
ALEXION PHARMACEUTICALS INC ALXN 2021-07-21 20:15:04 UTC -0.17 0.25 3900000
ALEXION PHARMACEUTICALS INC ALXN 2021-07-21 19:45:03 UTC -0.17 0.25 3900000
ALEXION PHARMACEUTICALS INC ALXN 2021-07-21 19:15:02 UTC -0.17 0.25 3900000
ALEXION PHARMACEUTICALS INC ALXN 2021-07-21 18:45:03 UTC -0.17 0.25 3900000
ALEXION PHARMACEUTICALS INC ALXN 2021-07-21 18:15:03 UTC -0.17 0.25 3900000
ALEXION PHARMACEUTICALS INC ALXN 2021-07-21 17:45:03 UTC -0.17 0.25 3900000
ALEXION PHARMACEUTICALS INC ALXN 2021-07-21 17:15:03 UTC -0.17 0.25 3900000
ALEXION PHARMACEUTICALS INC ALXN 2021-07-21 16:45:03 UTC -0.17 0.25 3900000
ALEXION PHARMACEUTICALS INC ALXN 2021-07-21 16:15:03 UTC -0.17 0.25 3900000
ALEXION PHARMACEUTICALS INC ALXN 2021-07-21 15:45:03 UTC -0.17 0.25 3900000
ALEXION PHARMACEUTICALS INC ALXN 2021-07-21 15:15:02 UTC -0.17 0.25 3900000
ALEXION PHARMACEUTICALS INC ALXN 2021-07-21 14:45:02 UTC -0.17 0.25 3900000
ALEXION PHARMACEUTICALS INC ALXN 2021-07-21 14:15:03 UTC -0.17 0.25 3900000
ALEXION PHARMACEUTICALS INC ALXN 2021-07-21 13:45:03 UTC -0.17 0.25 3900000
ALEXION PHARMACEUTICALS INC ALXN 2021-07-21 13:15:03 UTC -0.17 0.25 3900000
ALEXION PHARMACEUTICALS INC ALXN 2021-07-21 12:45:03 UTC -0.17 0.25 3900000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
AGF Investments Trust- AGFIQ Hedged Dividend Income Fund ALXN -51.0 shares, $-7798.41 2021-03-31 N-PORT

Elevate your investments